Recently, 2,3-diphenyl-1,4-diazaanthraquinone (DPBQ) 62 was proven to be a selective lead compound for the treatment of high-ploidy breast cancer, which activates p53 and triggers apoptosis of tumor cells (Figure 5) [78]. The gene discussed is TP53; the disease is breast carcinoma.